Search results for "Ingredient"

showing 10 items of 869 documents

Efficacy of an amine fluoride-triclosan mouthrinse as compared to the individual active ingredients

2003

Background: The purpose of the clinical study was to examine the antibacterial and plaque-reducing properties of mouthrinses containing triclosan (TRI), amine fluoride (AmF), and the combination of both (AFT) on 4-day plaque regrowth. A placebo solution (PLA) and a 0.2% chlorhexidine solution (CHX) served as negative and positive controls, respectively. Materials & Methods: After a professional tooth cleaning (day 0), 15 volunteers refrained from all mechanical oral hygiene measures for the next 96 h and rinsed instead twice daily for 1 min with 10 ml of one of the five randomly assigned solutions. Plaque index (PlI), which was assessed after 24 and 96 h (PlI1, PlI2), and plaque area of the…

Active ingredientbusiness.industryChemistryChlorhexidineAmine fluorideBiofilmDentistryPlaceboOral hygieneTriclosanchemistry.chemical_compoundStatistical significancemedicinePeriodonticsbusinessmedicine.drugJournal of Clinical Periodontology
researchProduct

The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs.

2013

The Biopharmaceutics Classification System (BCS) defines the solubility characteristics of an active pharmaceutical substance based on its dose-solubility ratio: for highly soluble drugs this ratio is less than 250 mL over a defined pH range. Prior to the revision of the European Medicines Agency (EMA, formerly EMEA) guideline in 2010, the "dose" in this ratio was consistently defined by the US FDA, the EMA, and the WHO biowaiver guidelines as the highest dosage strength. However, in the revised EMA guideline, the dose is defined as the highest single dose administered according to the Summary of Product Characteristics. The new EMA criterion for highly soluble may be closer to the actual c…

Active ingredientbusiness.industryMetoclopramidePharmaceutical ScienceGuidelineBioequivalencePharmacologyBiopharmaceutics Classification SystemBiopharmaceuticsSolubilityVerapamilPh rangeMedicineHumansRegulatory scienceDosingSummary of Product CharacteristicsbusinessJournal of pharmaceutical sciences
researchProduct

2006

Active ingredientbusiness.industryPharmaceutical ScienceMedicineGeneral MedicinePharmaceutical sciencesbusinessBiotechnologyManagementEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Six-Step Gram Scale Synthesis of the HIV Integrase Inhibitor Dolutegravir Sodium

2021

A short and practical synthesis for preparing the active pharmaceutical ingredient dolutegravir sodium was investigated. The convergent strategy developed herein starts from 3-(R)-amino-1- butanol and builds up the BC ring system in 76% isolated yield over four steps. Ring A was constructed by a one-pot 1,4-addition to diethyl-(2E/Z)-2-(ethoxymethylidene)-3-oxobutandioate and subsequent MgBr2·OEt2-mediated regioselective cyclization. Amide formation with 2,4- difluorobenzylamine was either performed from the carboxylic acid or through aminolysis of the corresponding ester precursor. Final salt formation afforded dolutegravir sodium in 48–51% isolated yield (HPLC-purity: 99.7–99.9%) over six…

Active ingredientchemistry.chemical_classificationbiologyChemistryStereochemistryCarboxylic acidButanolRegioselectivityIntegrasechemistry.chemical_compoundAminolysisYield (chemistry)Amidebiology.protein
researchProduct

Leukocyte migration test (LMT) in patients with thyroid disease: the response to human thyroid subcellular fractions.

1981

The response of circulating leukocytes to thyroid subcellular fractions was investigated in 19 patients with Graves' disease, 15 patients with Hashimoto's thyroiditis, 7 patients with toxic adenoma, 19 patients with nontoxic goiter and in 10 healthy students as control subjects. For this purpose, the leukocyte migration test of Soborg and Bendixen was performed against human crude thyroid extract (CTE), cell plasma membranes, nuclei, ribosomes, mitochondria and microsomes. Our results show positive LMT against: 1) CTE in patients with Graves' disease (61 +/- 13, p less than 0.001) and Hashimoto's thyroiditis (65 +/- 11, p less than 0.001) compared to controls (90 +/- 11); 2) cell plasma mem…

AdenomaAdultMaleendocrine systemmedicine.medical_specialtyLeukocyte migrationendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismCellThyroid GlandThyroiditisEndocrinologyInternal medicinemedicineLeukocytesHumansIn patientbusiness.industryGoiterThyroid diseaseThyroidThyroiditis AutoimmuneMiddle Agedmedicine.diseaseThyroid DiseasesGraves Diseasemedicine.drug_formulation_ingredientmedicine.anatomical_structureEndocrinologyCell Migration InhibitionMicrosomeFemalebusinessThyroid extractSubcellular FractionsJournal of endocrinological investigation
researchProduct

A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects.

2013

A limited amount of research suggests that oral ingestion of pinitol (3-O-methyl-d-chiro-inositol) positively influences glucose tolerance in humans. This study assessed the effects of different doses of pinitol supplementation on glucose tolerance, insulin sensitivity and plasma pinitol concentrations. Thirty healthy subjects underwent two one-day trials in which they consumed a nutritive beverage (Fruit Up®) containing 2.5, 4.0 or 6.0g of pinitol and a corresponding placebo equivalent in both energy and carbohydrates. Blood samples were collected frequently over the 240-min test period. The pinitol-enriched beverage reduced serum glucose and insulin at 45 and 60min, but only at a dose of …

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBlood sugarDown-RegulationPlaceboAnalytical ChemistryBeverageschemistry.chemical_compoundIngredientBlood serumInternal medicinemedicineIngestionHumansInsulinPinitolbusiness.industryInsulinGeneral MedicineEndocrinologychemistryBlood chemistryHyperglycemiaFemalebusinessInositolFood Science
researchProduct

Carriage of Enterobacteria Producing Extended-Spectrum β-Lactamases and Composition of the Gut Microbiota in an Amerindian Community

2015

ABSTRACT Epidemiological and individual risk factors for colonization by enterobacteria producing extended-spectrum beta-lactamases (E-ESBL) have been studied extensively, but whether such colonization is associated with significant changes in the composition of the rest of the microbiota is still unknown. To address this issue, we assessed in an isolated Amerindian Guianese community whether intestinal carriage of E-ESBL was associated with specificities in gut microbiota using metagenomic and metatranscriptomic approaches. While the richness of taxa of the active microbiota of carriers was similar to that of noncarriers, the taxa were less homogeneous. In addition, species of four genera,…

AdultMale0301 basic medicinefood.ingredient030106 microbiologyGene ExpressionGut floradigestive systembeta-LactamasesCoprococcusMicrobiologyFeces03 medical and health sciencesfluids and secretionsfoodEnterobacteriaceaeMechanisms of ResistancePhylogeneticsRNA Ribosomal 16SHumansPharmacology (medical)ColonizationPhylogenyAgedPharmacologybiologyEnterobacteriaceae InfectionsSequence Analysis DNAMiddle Agedbiology.organism_classificationParabacteroidesDesulfovibrioEnterobacteriaceaeFrench GuianaGastrointestinal Microbiomestomatognathic diseasesInfectious DiseasesGenes BacterialMetagenomicsCarrier StateIndians North AmericanbacteriaMetagenomeDesulfovibrioFemaleTranscriptomeAntimicrobial Agents and Chemotherapy
researchProduct

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics.

2010

The goal of this study was to investigate the in vitro-in vivo correlation (IVIVC) for fenofibrate immediate release (IR) tablet formulations based on MeltDose-technique. The in vitro determined drug solubility and permeability data were related to the C(max) values observed from two in vivo human studies. Solubility and permeation studies of fenofibrate were conducted in medium simulating the fasted state conditions in the upper jejunum, containing the surfactant compositions of the six formulations at different concentrations. The behavior of all surfactant compositions was characterized by surface tension, dynamic light scattering, and cryo-TEM. The obtained solubility and permeation dat…

AdultMalePharmaceutical ScienceBiological AvailabilityIn Vitro TechniquesDosage formPermeabilityIVIVCPulmonary surfactantPharmacokineticsFenofibrateMicroscopy Electron TransmissionIn vivomedicineHumansSolubilityChromatography High Pressure LiquidAgedActive ingredientFenofibrateChromatographyChemistryMiddle AgedJejunumSolubilityFemaleSpectrophotometry Ultravioletmedicine.drugTabletsJournal of pharmaceutical sciences
researchProduct

Prevalence of herpes simplex, Epstein Barr and human papilloma viruses in oral lichen planus.

2011

Objectives: The aim of the present study was to assess the prevalence of Herpes Simplex virus, Epstein Barr virus and Human Papilloma virus -16 in oral lichen planus cases and to evaluate whether any clinical variant, histopathological or demographic feature correlates with these viruses. Study Design: The study was conducted on 65 cases. Viruses were detected immunohistochemically. We evaluated the histopathological and demographic features and statistically analysed correlation of these features with Herpes Simplex virus, Epstein Barr virus and Human Papilloma virus-16 positivity. Results: Herpes Simplex virus was positive in six (9%) cases and this was not statistically significant. The …

AdultMaleSimplexvirusHerpesvirus 4 Humanfood.ingredientvirusesmedicine.disease_causeVirusYoung Adultfoodstomatognathic systemmedicineHumansSimplexvirusskin and connective tissue diseasesGeneral DentistryPathologicalAgedHuman papillomavirus 16integumentary systembusiness.industryEpstein-Barr Virus PositiveMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Epstein–Barr virusVirologystomatognathic diseasesHerpes simplex virusCross-Sectional StudiesOtorhinolaryngologyImmunologyUNESCO::CIENCIAS MÉDICASPapillomaSurgeryOral lichen planusFemalebusinessLichen Planus OralMedicina oral, patologia oral y cirugia bucal
researchProduct